• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    IM Cannabis Announces Form F-3 Resale Registration Statement Filing

    6/9/26 5:24:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $IMCC alert in real time by email

    TORONTO and GLIL YAM, Israel, June 9, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a medical cannabis company with operations in Israel and Germany, announces that, further to its press releases dated May 7, 2026 and  June 3, 2026, it has filed a resale registration statement on Form F-3 (the "Resale Registration Statement") with the Securities and Exchange Commission (the "SEC"). 

    The Resale Registration Statement registered an aggregate of 17,276,931 common shares in the capital of the Company ("Common Shares") comprised of: (i) up to 4,000,000 Common Shares issued or issuable upon the conversion of a convertible promissory note dated April 6, 2026, in the principal amount of US$250,000 and accrued interest (the "April 2026 Promissory Note"); (ii) 6,720,000 Common Shares issued or issuable upon the conversion of a convertible promissory note dated May 7, 2026, in the principal amount of US$300,000 and accrued interest (the "May 2026 Promissory Note"); (iii) 4,375,000 Common Shares issued or issuable upon the conversion of a convertible promissory note dated June 3, 2026, in the principal amount of US$225,000 and accrued interest (the "June 2026 Promissory Note"); (iv) 272,861 Common Shares issuable upon the exercise of a Common Share purchase warrant accompanying the April 2026 Promissory Note; (v) 1,127,820 Common Shares issuable upon the exercise of a Common Share purchase warrant accompanying the May 2026 Promissory Note; and (vi) 781,250 Common Shares issuable upon the exercise of a Common Share purchase warrant accompanying the June 2026 Promissory Note.

    The Resale Registration Statement has been filed with the SEC but has not yet become effective. A copy of the Resale Registration Statement will be available on the Company's issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. If declared effective by the SEC, the selling shareholders may use the prospectus relating to the Resale Registration Statement from time to time to resell the securities registered under the Resale Registration Statement. The Company will not receive any proceeds from the sale of any of the Common Shares by the selling shareholders.

    This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the Company's securities, including the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About IM Cannabis Corp.

    IMC (NASDAQ:IMCC) is an international company focused on building and scaling innovative businesses and technologies across global markets. The Company currently operates a medical cannabis platform serving patients in Israel and Germany while evaluating opportunities to expand into additional technology-driven sectors.

    The IMC ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms, in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

    Disclaimer for Forward-Looking Statements

    This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, "forward-looking statements"). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to the review of the Resale Registration Statement by the SEC; the timing of, and whether, the Resale Registration Statement may be declared effective by the SEC; and the ability of the selling shareholders to resell the securities covered by the Resale Registration Statement pursuant to the prospectus, if and when the Resale Registration Statement is declared effective.

    These forward-looking statements are based on a number of assumptions, including, among others: that the SEC review process will proceed in the ordinary course; that no material delays, objections or changes will arise in connection with the Resale Registration Statement; that the Company will continue to satisfy applicable regulatory and listing requirements; and that other factors relevant to the Resale Registration Statement and the resale of the underlying securities will not change in a material adverse manner.

    Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: risks that the resale registration statement may not be declared effective on the timeline anticipated by the Company or at all; the possibility of changes in applicable laws, rules or regulatory requirements; the Company's ability to continue to comply with applicable listing requirements; adverse market conditions; and the other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual report for the year ended December 31, 2025, which is available on the Company's issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. 

    Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements, except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

    Company Contact:

    Michal Efraty

    Investor & Public Relations

    IM Cannabis Corp.

    michal@efraty.com

    Oren Shuster, Chief Executive Officer

    IM Cannabis Corp.

    info@imcannabis.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/im-cannabis-announces-form-f-3-resale-registration-statement-filing-302795829.html

    SOURCE IM Cannabis Corp.

    Get the next $IMCC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMCC

    DatePrice TargetRatingAnalyst
    10/5/2021$8.00Buy
    ROTH Capital
    7/14/2021Buy
    Desjardins
    7/14/2021$10.50Buy
    Desjardins
    More analyst ratings

    $IMCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IM Cannabis Corp. Enters into Letter of Intent to Sell its European Activities, Expects to Significantly Reduce Debt by CAD$10.5 million

    Transaction Expected to Streamline Operations, Retain Israeli Business, Improve Working Capital through debt reduction and Cash Flow While Enabling the Pursuit of New Investment Opportunities as Previously AnnouncedTORONTO and GLIL YAM, Israel, June 18, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a medical cannabis company with operations in Israel and Germany, is pleased to announce that it has entered into a non-binding letter of intent (the "Letter of Intent") with Slil.com Holding Ltd., a privately-held Israeli entity beneficially owned and controlled by Oren Shuster, the Company's Chief Executive Officer, a director and debtholder of IMC ("Slil"), purs

    6/18/26 7:32:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Announces Form F-3 Resale Registration Statement Filing

    TORONTO and GLIL YAM, Israel, June 9, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a medical cannabis company with operations in Israel and Germany, announces that, further to its press releases dated May 7, 2026 and  June 3, 2026, it has filed a resale registration statement on Form F-3 (the "Resale Registration Statement") with the Securities and Exchange Commission (the "SEC").  The Resale Registration Statement registered an aggregate of 17,276,931 common shares in the capital of the Company ("Common Shares") comprised of: (i) up to 4,000,000 Common Shares issued or issuable upon the conver

    6/9/26 5:24:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing

    TORONTO and GLIL YAM, Israel, June 3, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a medical cannabis company with operations in Israel and Germany, today announced the closing of a US$225,000 convertible note financing in a private placement with an institutional investor (the "Lender"). Pursuant to a note purchase agreement between the Company and Lender dated June 3, 2026 (the "June Note Purchase Agreement"), the Company issued the Lender a note in the principal amount of US$225,000, with an original issuance discount of 10% (the "June Note").The June Note bears interest at a rate of 8% per annum, increasing to 14% upon the occurrence and continuation of

    6/3/26 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    SEC Filings

    View All

    SEC Form 6-K filed by IM Cannabis Corp.

    6-K - IM Cannabis Corp. (0001792030) (Filer)

    6/18/26 7:57:29 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form EFFECT filed by IM Cannabis Corp.

    EFFECT - IM Cannabis Corp. (0001792030) (Filer)

    6/17/26 12:16:07 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by IM Cannabis Corp.

    6-K - IM Cannabis Corp. (0001792030) (Filer)

    6/9/26 5:28:37 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH Capital initiated coverage on IM Cannabis with a new price target

    ROTH Capital initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $8.00

    10/5/21 7:57:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    Desjardins initiated coverage on IMC Mortgage Co

    Desjardins initiated coverage of IMC Mortgage Co with a rating of Buy

    7/14/21 8:40:32 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    Desjardins initiated coverage on IM Cannabis with a new price target

    Desjardins initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $10.50

    7/14/21 7:01:53 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Financials

    Live finance-specific insights

    View All

    IM Cannabis Corp. Announces First Quarter 2026 Financial Results

    TORONTO and GLIL YAM, Israel, May 13, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a medical cannabis company with operations in Israel and Germany, today announced its financial results for the first quarter ended March 31, 2026. All amounts were reported in Canadian dollars, unless otherwise stated. For the three months ended March 31, 2026, the Company recorded revenues of $8.7 million, gross profit of $1.4 million, operating loss of $1.7 million, and a net loss of $2.5 million, or $0.38 per share. The Company also continued to advance its co

    5/13/26 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Reports Third Quarter 2025 Financial Results

    TORONTO and GLIL YAM, Israel, Nov. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the third quarter and nine months ended September 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter and nine months ended September 30, 2024, unless otherwise stated. Q3 2025 Financial Highlights:  Consistent Revenue for Q3 2025 and 2024 of $13.9 million.13% Gross profit decrease vs. Q3 2024 of $2.7 million vs. $3.1 million.13% Gross Margin decrease vs. Q3 2024 of 20% vs. 23%. $3.1 million One time goodwill and intangible asset impairment in Q3 2025 Operating

    11/13/25 9:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Announces Warrant Amendments and Form F-3 Resale Registration Statement Filing

    TORONTO and GLIL YAM, Israel, Aug. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a "Holder") of common share purchase warrants ("November 2024 Warrants") issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to: (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to C$3.43; and (y) extend the expiration date of each November 2024 Warrant from November 12, 2026 to July 31, 2030 (together, the "Transaction"). Form F-3 Resale Registration Statement The

    8/13/25 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Leadership Updates

    Live Leadership Updates

    View All

    IM Cannabis Announces the Appointment of Mr. Alon Dayan to its Board of Directors

    TORONTO and GLIL YAM, Israel, Jan. 5, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), medical cannabis company with operations in Israel and Germany, announced today that Mr. Alon Dayan has been appointed to the Company's board of directors effective December 31, 2025. Mr. Dayan, who is currently the Chief Executive Officer of KeepZone AI Inc., a position he has held since 2025, brings over 15 years of executive experience in the homeland security technology sector, with a proven track record of founding and scaling innovative companies focused on systems integration, secure communications, and international business development. As the founder and Chief Execu

    1/5/26 8:55:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Appoints Asi Levi as Chief Financial Officer

    TORONTO and GLIL YAM, Israel, Dec. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced, further to its press release dated October 29, 2025, the appointment of Asi Levi, CPA, as the Company's Chief Financial Officer ("CFO"), effective immediately, to replace Uri Birenberg. Mr. Levi has over 15 years of experience in finance and controlling roles, including serving as Chief Financial Officer of Water Ways Technologies Inc. and DekelOil CI, part of Dekel Agri-Vision Plc and as Controller of SciSparc Ltd. and A2Z Cust2Mate Solutions Corp. He has overseen fundraising efforts

    12/12/25 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

    TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ --  IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company's board of directors (the "Board") effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability. "We are thrilled to welcome Shmulik to our Board of Directors," said Oren Shuster, Chief Executive Officer of

    9/11/24 8:30:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $IMCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by IM Cannabis Corp.

    SC 13G - IM Cannabis Corp. (0001792030) (Subject)

    2/21/23 10:56:41 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by IM Cannabis Corp. (Amendment)

    SC 13D/A - IM Cannabis Corp. (0001792030) (Subject)

    2/8/23 1:29:15 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by IM Cannabis Corp. (Amendment)

    SC 13G/A - IM Cannabis Corp. (0001792030) (Subject)

    2/2/23 10:38:01 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care